Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Market Analysis & Valuation

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies203
  • 7D3.1%
  • 3M-1.6%
  • 1Y12.0%
  • YTD-1.6%

The market has climbed by 3.1% over the past week, with every sector up and the Healthcare sector leading the way. As for the past 12 months, the market is up 12%. As for the next few years, earnings are expected to grow by 10% per annum.

Market Valuation and Performance

Has the Swiss Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026CHF 1.9tCHF 783.4bCHF 110.0b20.4x17.6x2.5x
Tue, 03 Mar 2026CHF 2.1tCHF 777.6bCHF 113.5b21x18.3x2.7x
Thu, 29 Jan 2026CHF 2.0tCHF 789.2bCHF 113.8b20.5x17.4x2.5x
Sat, 27 Dec 2025CHF 2.0tCHF 794.7bCHF 114.0b20.3x17.4x2.5x
Mon, 24 Nov 2025CHF 1.9tCHF 807.6bCHF 115.3b19.1x16.5x2.4x
Wed, 22 Oct 2025CHF 1.9tCHF 774.0bCHF 90.4b19.3x21.1x2.5x
Fri, 19 Sep 2025CHF 1.8tCHF 773.0bCHF 90.1b19.4x20.4x2.4x
Sun, 17 Aug 2025CHF 1.8tCHF 777.4bCHF 90.3b21.2x20.4x2.4x
Tue, 15 Jul 2025CHF 1.8tCHF 784.9bCHF 106.7b20.4x17x2.3x
Thu, 12 Jun 2025CHF 1.8tCHF 782.7bCHF 106.6b20.3x17.3x2.4x
Sat, 10 May 2025CHF 1.8tCHF 787.3bCHF 106.1b19.8x16.9x2.3x
Mon, 07 Apr 2025CHF 1.7tCHF 843.7bCHF 158.3b17.9x10.8x2x
Wed, 05 Mar 2025CHF 1.9tCHF 807.8bCHF 117.2b20.4x16.3x2.4x
Fri, 31 Jan 2025CHF 1.9tCHF 818.6bCHF 117.9b21.9x15.8x2.3x
Sun, 29 Dec 2024CHF 1.7tCHF 816.1bCHF 117.6b20.9x14.8x2.1x
Tue, 26 Nov 2024CHF 1.7tCHF 811.1bCHF 117.1b20x14.9x2.2x
Thu, 24 Oct 2024CHF 1.8tCHF 807.2bCHF 114.4b21.5x15.9x2.2x
Sat, 21 Sep 2024CHF 1.8tCHF 802.8bCHF 114.0b21x15.7x2.2x
Mon, 19 Aug 2024CHF 1.8tCHF 805.2bCHF 114.0b21.9x16x2.3x
Wed, 17 Jul 2024CHF 1.8tCHF 800.3bCHF 125.2b21.5x14.7x2.3x
Fri, 14 Jun 2024CHF 1.8tCHF 799.9bCHF 125.5b21.7x14.5x2.3x
Sun, 12 May 2024CHF 1.8tCHF 801.7bCHF 126.0b21.5x14.1x2.2x
Tue, 09 Apr 2024CHF 1.8tCHF 768.1bCHF 97.2b21.6x18.1x2.3x
Thu, 07 Mar 2024CHF 1.7tCHF 772.8bCHF 99.3b20.4x17.4x2.2x
Sat, 03 Feb 2024CHF 1.7tCHF 758.6bCHF 109.4b18.1x15.4x2.2x
Mon, 01 Jan 2024CHF 1.7tCHF 758.5bCHF 108.9b18.4x15.4x2.2x
Wed, 29 Nov 2023CHF 1.6tCHF 770.1bCHF 110.9b18x14.6x2.1x
Fri, 27 Oct 2023CHF 1.6tCHF 758.1bCHF 100.8b17.7x15.4x2.1x
Sun, 24 Sep 2023CHF 1.7tCHF 754.5bCHF 100.0b18.3x16.6x2.2x
Tue, 22 Aug 2023CHF 1.6tCHF 745.0bCHF 75.1b17.9x21.8x2.2x
Thu, 20 Jul 2023CHF 1.7tCHF 749.8bCHF 76.7b18.9x22.2x2.3x
Sat, 17 Jun 2023CHF 1.7tCHF 757.1bCHF 76.9b19.4x22.7x2.3x
Mon, 15 May 2023CHF 1.8tCHF 786.9bCHF 81.4b19.3x21.8x2.3x
Wed, 12 Apr 2023CHF 1.8tCHF 778.3bCHF 69.2b19.2x25.3x2.3x
Price to Earnings Ratio

25.3x


Total Market Cap: CHF 1.8tTotal Earnings: CHF 69.2bTotal Revenue: CHF 778.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Market Price to Earnings3Y Average 17x202420252026
Current Market PE
  • Investors are relatively neutral on the Swiss market at the moment, indicating that they expect earnings will grow in line with historical growth rates.
  • The market is trading close to its 3-year average PE ratio of 17.0x.
Past Earnings Growth
  • The earnings for Swiss listed companies have grown 17% per year over the last three years, while revenues have remained steady.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Sector Trends

Which sectors have driven the changes within the Swiss Market?

CH Market3.13%
Utilities5.44%
Financials4.44%
Consumer Discretionary3.58%
Industrials3.16%
Real Estate2.96%
Tech2.93%
Healthcare2.93%
Consumer Staples2.40%
Materials1.94%
Telecom1.20%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 29.6x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 20.9% which is higher than its past year's earnings decline of 30.9% per year.
  • The Financials sector is the least preferred by investors for future growth, which is trading close to its 3-year average of 7.5x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 21% over the next 5 years.
  • This is better than its past earnings decline of 31% per year.
  • In contrast, the Real Estate sector is expected to see its earnings decline by 6.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NOVN NovartisCHF 123.203.4%
+CHF 7.7b		33.9%PE21xHealthcare
UBSG UBS GroupCHF 31.437.0%
+CHF 6.3b		35.1%PE15.6xFinancials
NESN NestléCHF 78.372.6%
+CHF 5.1b		-10.3%PE22.3xConsumer Staples
ABBN ABBCHF 65.844.3%
+CHF 4.9b		60.4%PE32.7xIndustrials
ROP Roche HoldingCHF 318.001.8%
+CHF 4.4b		21.5%PE19.6xHealthcare
See more

Market Insights

Header cover image
What’s happening with Renewables & EVs?
Richard Bowman avatar
Richard Bowman
Part 1 of 3 in our “What’s happening with…” series, where we look back on the investment themes that were all the rage just a few years ago and see how they're doing now.
Continue reading
How to spot the winners in 2026's IPOs

Latest News

ZURN
CHF 570.80
Zurich Insurance Group
7D
4.2%
1Y
1.0%
AEVS
CHF 12.85
Aevis Victoria
7D
-4.8%
1Y
6.2%
SWON
CHF 6.31
SoftwareOne Holding
7D
-7.1%
1Y
28.9%
SIGN
CHF 11.63
SIG Group
7D
-1.4%
1Y
-25.1%

SIGN: Bullish Outlook Hinges On Confirmed 2026 Sales And Margin Guidance

The analyst price target for SIG Group has been raised from CHF 12.27 to CHF 14.00. Analysts cite updated fair value estimates, revised growth and margin assumptions, and recent price target and rating changes at firms including Citi, UBS, Goldman Sachs and Jefferies as key drivers of the shift.
ABBN
CHF 65.84
ABB
7D
4.3%
1Y
60.4%

ABBN: Data Center Hopes Will Struggle To Support Elevated Future P/E

ABB's updated fair value estimate has moved to CHF 52.89 from CHF 51.51 as analysts lift price targets by CHF 5 to CHF 7 and point to improving earnings expectations, particularly around data center related demand and a more supportive valuation backdrop. Analyst Commentary Recent Street research on ABB highlights a generally constructive tone around the shares, with several banks lifting price targets in CHF terms and pointing to an improved earnings outlook tied to data center related demand and a more supportive valuation backdrop.
ROP
CHF 318.00
Roche Holding
7D
1.8%
1Y
21.5%
KNIN
CHF 187.25
Kuehne + Nagel International
7D
9.2%
1Y
3.7%
NESN
CHF 78.37
Nestlé
7D
2.6%
1Y
-10.3%
UBSG
CHF 31.43
UBS Group
7D
7.0%
1Y
35.1%

UBSG: Capital Flexibility And Buybacks Will Drive Future Repricing Potential

UBS Group's updated analyst price target edges higher to CHF 51.07 from CHF 50.79, as analysts factor in slightly lower assumed revenue growth, a modestly higher profit margin, and a small adjustment to the forward P/E multiple. Analyst Commentary Recent Street research on UBS Group shows a mix of views, with some analysts trimming price targets and others setting higher levels.
GEBN
CHF 530.20
Geberit
7D
-0.4%
1Y
-0.2%

GEBN: Future Margins And P/E Will Likely Support Balanced Return Potential

The updated analyst price target for Geberit narrows to CHF 575 from CHF 588. This reflects a cluster of recent target trims by banks and slightly softer assumptions for revenue growth, profit margins and future P/E multiples in current models.
DKSH
CHF 58.20
DKSH Holding
7D
-2.3%
1Y
-0.9%
BLKB
CHF 1,110.00
Basellandschaftliche Kantonalbank
7D
-5.5%
1Y
27.3%
KARN
CHF 242.50
Kardex Holding
7D
-2.2%
1Y
20.0%
NOVN
CHF 123.20
Novartis
7D
3.4%
1Y
33.9%

NOVN: Dermatology Pipeline, RLT Expansion And Dividend Will Shape Balanced Returns

Analysts have modestly raised their Novartis price target from CHF 117.49 to CHF 121.50, citing updated assumptions for revenue growth, profit margins and future P/E as key drivers of the revision. What's in the News Cosentyx received US FDA approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor available for this group and expanding Novartis' dermatology footprint in a chronic inflammatory skin disease that often begins around puberty.
CFR
CHF 142.90
Compagnie Financière Richemont
7D
3.5%
1Y
5.2%
RSGN
CHF 19.70
R&S Group Holding
7D
-5.5%
1Y
15.9%

R&S Group Holding AG (VTX:RSGN) Shares Could Be 37% Below Their Intrinsic Value Estimate

Feb 04
R&S Group Holding AG (VTX:RSGN) Shares Could Be 37% Below Their Intrinsic Value Estimate